<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58618">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798134</url>
  </required_header>
  <id_info>
    <org_study_id>TANDEM 2012-001 OUS</org_study_id>
    <nct_id>NCT01798134</nct_id>
  </id_info>
  <brief_title>Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma</brief_title>
  <acronym>MIRACLE I</acronym>
  <official_title>Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CeloNova BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CeloNova BioSciences, Inc.</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, prospective, pilot, Multicenter Study of DEB-TACE using
      Doxorubicin-Loaded Embozene® Tandem™ Microspheres to treat HCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Patients with SAEs</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>• Study Efficacy Goals:
Freedom of primary tumor progression at 6 months (EASL and mRECIST)
Average time to progression in all patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Progression</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Tumor control</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary objectives include:
Local tumor control based on the devascularization pattern.  If any patient is referred to liver transplantation: Local tumor control based on microscopic analysis
12 month survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>DEB-TACE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)
Treatment: Lobes;                                                   Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TANDEM™</intervention_name>
    <arm_group_label>DEB-TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a confirmed diagnosis of HCC according to the EASL criteria for
             diagnosis, and staged according to the BCLC criteria

          2. Subject is competent and willing to provide written informed consent in order to
             participate in the study

          3. Adults (male or female) patients ≥ 18 years of age

          4. ECOG performance status 0-2 or Child Pugh classification is 0-11

          5. Multidonar or single nodular tumor ≥3-10cm, Patients with bilobar disease who can be
             treated superselectively in a single session or both lobes able to be treated within
             3-5 weeks. Patient must have at least one tumor lesion that meets the following
             criteria: Lesion can be accurately measured in at least one dimension according to
             mRECIST criteria

          6. No invasion in the major blood vessel (hepatic portal, hepatic vein) or bile duct by
             the MRI or CT

          7. Proper blood, liver, renal, heart function: testing result within 2 weeks from
             registry of this study

          8. No current infections requiring antibiotic therapy

          9. Not actively on cumarin based anticoagulation or suffering from a known bleeding
             disorder

         10. Measurable disease per the Response Evaluation Criteria in Solid Tumors (mRECIST)

         11. Expected survival  more than 6 months

        Exclusion Criteria:

          1. ECOG performance status &gt;2; or Child-Pugh class C11 or more, or ASA class 5

          2. Bilirubin levels &gt;3 mg/dl

          3. HCC with large vessel or biliary duct invasion, diffuse HCC or extrahepatic spread

          4. Patients in which any of the following are contraindicated or present:

               -  The use of doxorubicin

               -  MRI

               -  Hepatic embolization procedures

               -  WBC &lt; 3000 cells/mm3

               -  neutrophil &lt; 1500 cells/mm3

               -  Cardiac ejection fraction &lt; 50 percent assessed by isotopic ventriculography,
                  echocardiography or MR

               -  Elevated creatinine greater than or equal to 2.5 mg/dl

               -  Impaired clotting test (platelet count &lt; 5 x 104/mm3, PT-INR &gt; 2.0)

               -  AST and/or ALT &gt;5x ULN or, when greater &gt;250 U/L

               -  Known hepatofugal blood flow

               -  Arterio-venous shunt

               -  Arterio-portal shunt

               -  Main stem portal vein occlusion(point 6 in inclusion criteria)

          5. Women who are pregnant or breast feeding

          6. Allergy to iodinated contrast used for angiography

          7. Tumour burden of more than 50% of liver

          8. Patients with objective signs of active bacterial, viral (HIV),  or fungal infection

          9. Other primary malignancies or evidence of metastatic disease

         10. Patients previously treated with anthracyclines (other than doxorubicin).

         11. Any co-morbid disease or condition or event that, in the investigator's judgment,
             would place the patient at undue risk that would preclude the safe use of DEB-TACE.

         12. Under no circumstances should patients be enrolled in this study who is already
             participating in another study for treatment of primary liver cancer.

         13. Under no circumstances should patients be enrolled in this study who has received any
             other embolotherapy (including SIRT) for the treatment of primary liver cancer.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gotz M Richter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Stuttgart - Katharinenhospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Demant-Bauchspiess</last_name>
    <phone>+49 0 7319331140</phone>
    <email>edemant-bauchspiess@celonova.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Hart</last_name>
    <phone>210-489-4025</phone>
    <email>jhart@celonova.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Universitat Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Schmitz</last_name>
      <phone>0049 622 156 35667</phone>
    </contact>
    <investigator>
      <last_name>Ulrike Stampfl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Huber</last_name>
      <phone>0049 713 149 3800</phone>
    </contact>
    <investigator>
      <last_name>Philippe Pereira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart- Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny SEIDEL</last_name>
      <phone>0049 711 278 34415</phone>
    </contact>
    <investigator>
      <last_name>Gotz M Richter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Schweinhuber</last_name>
      <phone>0049 899 270 2201</phone>
    </contact>
    <investigator>
      <last_name>Thomas Helmberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kilinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Steinmetz</last_name>
      <phone>0049 615 110 76771</phone>
    </contact>
    <investigator>
      <last_name>Peter Huppert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thore Brink</last_name>
      <phone>0049 201 723 85509</phone>
    </contact>
    <investigator>
      <last_name>Jens Christian Altenbernd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Frankl</last_name>
      <phone>0049 941 944 7431</phone>
    </contact>
    <investigator>
      <last_name>Christian Stroszcynski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To show safety</keyword>
  <keyword>and efficacy</keyword>
  <keyword>investigational product</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
